Speaking to CNBC-TV18, Kiran Mazumdar Shaw, chairman and ,managing director of Biocon said," I am glad that NPPA has given us this price increase. It still puts us at a discount to other multinationals and importers of insulin but at least one step at a time."
first published: Mar 17, 2011 05:10 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
Pine Labs’ Rs 3,900 Cr IPO| CEO Amrish Rau On Why The Issue Size Was Cut & The Post-IPO Gameplan
Can Nifty Claw Back Above 25,600 Or Will Sensex Expiry Cap The Upside?| Opening Bell Live
Gold ETFs vs Silver ETFs | Which One Is Your Wealth Buddy?
